Literature DB >> 20543608

Postexposure prophylaxis for HIV following sexual exposure.

Tristan J Barber1, Paul D Benn.   

Abstract

PURPOSE OF REVIEW: Postexposure prophylaxis (PEP) has become an important part of combined approaches to the prevention of onward HIV transmission. As PEP becomes more widely available after sexual as well as occupational exposure, there are ongoing debates about cost-effectiveness and utility. Different regions have adopted different PEP strategies and the availability of new antiretroviral drugs and classes means that options for PEP regimens are increasing. This review is timely and of importance as it summarizes the evidence supporting current PEP usage and discusses potential future strategies for PEP prescribing. RECENT
FINDINGS: This review covers the biology and risk of HIV transmission and evidence supporting the use of PEP. It gives a summary of current guidelines including which agents to use, the potential for drug-drug interactions, possible alternative and potential novel PEP regimens, cost-effectiveness and research on effects of PEP on sexual behaviour.
SUMMARY: While reinforcing current practice around PEP prescribing, this review discusses possible future developments including the use of new antiretroviral drugs, new classes of antiretroviral drugs or novel strategies for PEP which are likely to be areas of research in the near future.

Mesh:

Substances:

Year:  2010        PMID: 20543608     DOI: 10.1097/COH.0b013e32833a5e6c

Source DB:  PubMed          Journal:  Curr Opin HIV AIDS        ISSN: 1746-630X            Impact factor:   4.283


  6 in total

1.  Getting Personal: Progress and Pitfalls in HIV Prevention Among Latinas.

Authors:  Hortensia Amaro; Anita Raj; Elizabeth Reed; Monica Ulibarri
Journal:  Psychol Women Q       Date:  2011-12-01

Review 2.  Prevention of human immunodeficiency virus and AIDS: postexposure prophylaxis (including health care workers).

Authors:  Susan E Beekmann; David K Henderson
Journal:  Infect Dis Clin North Am       Date:  2014-10-05       Impact factor: 5.982

Review 3.  Clinical use of CCR5 inhibitors in HIV and beyond.

Authors:  Bruce L Gilliam; David J Riedel; Robert R Redfield
Journal:  J Transl Med       Date:  2011-01-27       Impact factor: 5.531

4.  HIV awareness and prevention strategies among transgender women in the Eastern and Southern United States: findings from the LITE Study.

Authors:  Rodrigo A Aguayo-Romero; Christopher M Cannon; Andrea L Wirtz; Erin E Cooney; Kenneth H Mayer; Sari L Reisner
Journal:  J Int AIDS Soc       Date:  2022-10       Impact factor: 6.707

5.  Pre-exposure and postexposure prophylaxes and the combination HIV prevention methods (The Combine! Study): protocol for a pragmatic clinical trial at public healthcare clinics in Brazil.

Authors:  Alexandre Grangeiro; Márcia Thereza Couto; Maria Fernanda Peres; Olinda Luiz; Eliana Miura Zucchi; Euclides Ayres de Castilho; Denize Lotufo Estevam; Rosa Alencar; Karina Wolffenbüttel; Maria Mercedes Escuder; Gabriela Calazans; Dulce Ferraz; Érico Arruda; Maria da Gloria Corrêa; Fabiana Rezende Amaral; Juliane Cardoso Villela Santos; Vivian Salles Alvarez; Tiago Kietzmann
Journal:  BMJ Open       Date:  2015-08-25       Impact factor: 2.692

6.  Adherence to Post-Exposure Prophylaxis (PEP) and Incidence of HIV Seroconversion in a Major North American Cohort.

Authors:  Réjean Thomas; Chrissi Galanakis; Sylvie Vézina; Danièle Longpré; Michel Boissonnault; Emmanuelle Huchet; Louise Charest; Daniel Murphy; Benoît Trottier; Nimâ Machouf
Journal:  PLoS One       Date:  2015-11-11       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.